Zoledronic acid

Sold as Zobone, Cipla zoledronic acid, Zolapor, Dronamyl, Zoledronic acid fresenius, Eurodron, Zoledronic acid accord, Zoldron, Zoledronic acid iv camox, Zoledronic acid iv austell, Zoledronic acid iv apex, Zoclasta, Zoltero, Bonazoll, Lonostio

C₅H₁₀N₂O₇P₂272.09 g/mol

(1-Hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid

Drag to rotate. Structure from PubChem CID 68740.

Loading Wikipedia summary

Registration

Applicants: 10
Registrations: 16
Schedule source: Consolidated Schedules 06 July 2026

Applicants and registrations

Applicant	Brands	Dosages	Registrations	Schedule	Leaflets
Ranbaxy Pharmaceutical (Pty) LtdCertificate held by Ranbaxy Pharmaceuticals (Pty) Ltd	Zobone	4 mg, 5 mL	420664, 471168	S4	PIL
Cipla Medpro (Pty) LtdCancelled	Cipla zoledronic acid	Not stated	430731	S4	None
Activo Health (Pty) Ltd	Zolapor	Not stated	450033	S4	None
Viatris Healthcare (Pty) Ltd	Dronamyl	4 mg/5 ml	470039	S4	None
Fresenius Kabi South Africa (Pty) Ltd	Zoledronic acid fresenius	4 MG/5 ML	470262	S4	None
Biomab Innovation (Pty) Ltd	Eurodron	Not stated	471126	S4	None
Accord Healthcare (Pty) Ltd	Zoledronic acid accord, Zoldron	4 MG/5 ML	480354, 480355	S4	None
Austell Pharmaceuticals (Pty) Ltd3 of 4 cancelled	Zoledronic acid iv camox, Zoledronic acid iv austell, Zoledronic acid iv apex, Zoclasta	5 mg/100 ml	490438, 490439, 490440, 491081	S4	None
Hetero Drugs South Africa (Pty) Ltd	Zoltero	Not stated	510202	S4	None
Innovata pharmaceuticalsCertificate held by Lnnovata Pharmaceuticals (Pty) Ltd	Bonazoll, Lonostio	5 mg	550903, 560851	S4	PI PIL

Variants

Product	Strength and form	Registration	Status	Schedule	Leaflets
Zobone EACH VIAL CONTAINS: ZOLEDRONIC ACID 4,0 mg	4 mgPowder for solution for infusion.	42066442/34/0664Approved 21 August 2026	Registered	S4	PIL
Cipla zoledronic acid EACH VIAL CONTAINS ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	43073143/34/0731	Cancelled	S4	None
Zolapor EACH 5,0 ml SOLUTION CONTAINS ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	45003345/34/0033	Registered	S4	None
Dronamyl 4 mg/5 ML EACH 5,0 mL SOLUTION CONTAINS: ZOLEDRONIC ACID 4,0 mg	4 mg/5 ml	47003947/32.2/0039	Registered	S4	None
Zoledronic acid 4 mg/5 ML fresenius Each 5 ml vial contains ZOLEDRONIC ACID MONOHYDRATE EQUIVALENT TO ZOLEDRONIC ACID (ANHYDROUS) 4,0 mg	4 MG/5 ML	47026247/34/0262	Registered	S4	None
Eurodron EACH 5,0 mL SOLUTION CONTAINS : ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	47112647/32.16/1126	Registered	S4	None
Zobone solution for infusion Each 5 ml vial contains: 4,264 mg ZOLEDRONIC ACID (AS MONOHYDRATE) EQUIVALENT TO ZOLEDRONIC ACID ANHYDROUS 4,0 mg	5 mLConcentrate for solution for infusion.	47116847/34/1168Approved 10 August 2022	Registered	S4	PIL
Zoledronic acid 4 mg/5 ML accord Each vial contains 4,264 mg ZOLEDRONIC ACID MONOHYDRATE EQUIVALENT TO ZOLEDRONIC ACID ANHYDROUS 4,0 mg	4 MG/5 ML	48035448/3.5/0354	Registered	S4	None
Zoldron Each vial contains 4,264 mg ZOLEDRONIC ACID MONOHYDRATE EQUIVALENT TO ZOLEDRONIC ACID ANHYDROUS 4,0 mg	Not listed	48035548/3.5/0355	Registered	S4	None
Zoledronic acid iv camox EACH 5,0 ml SOLUTION CONTAINS ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	49043849/34/0438	Cancelled	S4	None
Zoledronic acid iv austell EACH 5,0 ml SOLUTION CONTAINS ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	49043949/34/0439	Cancelled	S4	None
Zoledronic acid iv apex EACH 5,0 ml SOLUTION CONTAINS ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	49044049/34/0440	Cancelled	S4	None
Zoclasta 5 mg/100 ML EACH 100,0 ml SOLUTION CONTAINS ZOLEDRONATE TRISODIUM EQUIVALENT TO ZOLEDRONIC ACID 5,0 mg	5 mg/100 ml	49108149/34/1081	Registered	S4	None
Zoltero Each vial with 5 ml concentrate contains 4 mg ZOLEDRONIC ACID (ANHYDROUS) EQUIVALENT TO ZOLEDRONIC ACID MONOHYDRATE 4,264 mg	Not listed	51020251/34/0202	Registered	S4	None
Bonazoll 5 EACH 100,0 ml SOLUTION CONTAINS ZOLEDRONIC ACID MONOHYDRATE 5,0 mg	5 mgSolution for infusion	55090355/34/0903Approved 29 August 2023	Registered	S4	PI PIL
Lonostio EACH 5,0 ml SOLUTION CONTAINS ZOLEDRONIC ACID MONOHYDRATE EQUIVALENT TO ZOLEDRONIC ACID 4,0 mg	Not listed	56085156/34/0851	Registered	S4	None

Regulatory status

Where S4 sits on the scale

S0S1S2S3S4S5S6S7S8

Prescription-only medicine.

Schedule 4 covers most ordinary prescription medicines. You need a prescription from an authorised prescriber, such as a doctor or dentist, and a pharmacist dispenses it. Its price, name, pack size and strength can still be told to the public, as long as nothing links it to what it treats.

Schedule S4, matched to the Consolidated Schedules by ingredient, confidence high.

Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.

Consolidated Schedules listings for Zoledronic acid

S4: Zoledronic acid
Consolidated Schedules 06 July 2026, line 8422

Pharmacological class: Complementary Medicines: Health Supplements (class 34)

This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.

SAHPRA documents

Professional information (PI)For healthcare professionalsBonazoll 5, Innovata pharmaceuticals Patient information leaflet (PIL)For patients and carersZobone, Ranbaxy Pharmaceutical (Pty) Ltd

These documents are provided by SAHPRA for informational purposes. Always consult with a healthcare professional for medical advice.

Research articles

Loading PubMed articles

Background